Evidence map›Paper›PMID 25872530›Full record

ArticleTrials2015

Quality of randomized controlled trials reporting in the treatment of melasma conducted in China.

Zhiwei Chen, Yuchi Chen, Jingchun Zeng, Yang Wang, Teng Ye, Qiaochu Zhou, Xiaojing Du, Wenting Su, Zhishan Ding

Open access · goldAbstract read
In one paragraph

Article in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhiwei ChenDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. wz75czw@sina.cn.
Yuchi ChenCollege of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, China. btcyc@sina.com.
Jingchun ZengGuangzhou University of Chinese Medicine, Guangzhou, 510405, China. tcm_zjc@126.com.
Yang WangDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. 5486842@163.com.
Teng YeDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. yeteng902@163.com.
Qiaochu ZhouDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. transferzhou@163.com.
Xiaojing DuDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. 173046023@qq.com.
Wenting SuDepartment of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, 325000, Zhejiang Province, China. tinasu1211@163.com.
Zhishan DingZhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, China. 531749507@qq.com.
Wenzhou Hospital of Traditional Chinese Medicine · CNZhejiang Chinese Medical University · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China.

methodsSeveral databases were searched from their inception through to August 2014. In order to rate the report quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items ('randomization', 'allocation concealment', 'blinding', 'baseline characteristics' and 'intention-to-treat (ITT) analysis') were scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial.

resultsA total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of 4 and a maximum of 11. Some items' information was insufficient, especially in the categories of 'trial design', 'sample size', 'recruitment' and 'ancillary analyses' with a positive rate of less than 20%. The median MIS was 1 with a minimum of 0 and a maximum of 3. Some items' reporting was poor, especially in the categories of 'randomization', 'allocation concealment and implementation', 'blinding' and 'ITT analysis' with a positive rate of less than 10%. The mean OQS increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001). With regard to the MIS, no variable was statistically significant in the ordinal regression model.

conclusionThe reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of the CONSORT statement.

Indexed as

BibliometricsChinaData Interpretation, StatisticalHumansMelanosisPractice Guidelines as TopicQuality ControlRandomized Controlled Trials as TopicResearch DesignTime FactorsTreatment Outcome

Identifiers

PMID25872530
PMCPMC4399216
OpenAlexW2014613250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.